


AI-Pharma.Capital Fund

Specialized Hybrid Investment Fund for the AI in Pharma Industry



AI-Pharma is a hybrid investment fund specifically focused on the AI in Pharma and Drug Discovery sector, backed by seasoned professionals who have been active in both the investment banking and AI for Drug Discovery industries for years, long before the sector was recognized as a serious prospect by the overwhelming majority of investors, and some of whom made their first investments into the sector in 2014. The fund structures its portfolio based on sophisticated industry intelligence and comparative analytics provided by the Pharma Division of Deep Knowledge Analytics, the world-leading source of market intelligence on the AI for Drug Discovery, Biomarker Discovery and Advanced R&D sector, and which uses hundreds of quantitative and fact-based parameters to identify prospective investment targets for the fund, utilizing multidimensional analytical frameworks as complex as the industry itself.

AI for Drug Discovery, Biomarker Development and Advanced R&D is considered by the majority of experts and analysts as one of the most prospective sectors in the Pharma industry, with the greatest disruptive potential and capability to increase the efficiency and decrease the cost of developing new drugs, and to improve the performance and profitability of leading Pharma corporations. The sector currently consists of approximately 170 AI-companies, none of which are publicly traded yet, and 400 investors, 97% of which are venture funds. There is no one single specialized, thematic investment fund for this particular sector, and most of the 400 funds which are active in this sphere lack the specific expertise required for making deep due diligence on AI for Drug Discovery startups, especially given its increased complexity compared to the broader BioTech sector, which is multiplied even further by the sector's extremely high dynamic of innovations and new technology adoption.

**Hedged Risk
Through Maximum
Diversification**

**Venture 2.0
Novel InvestTech
Solutions**

**AI for Drug Discovery,
Biomarker Development
and Advanced R&D in
Healthcare**

**Backed by the World
Leader in AI in Pharma
Industry Intelligence
and Analytics**

**Fund Managers with
25+ Years of
Experience in the AI
in Pharma Industry**

Investment Thesis

The Fund will use highly diversified and de-risked strategy, seeking to acquire positions in at least 20 best companies out of 170 leading companies comprising the AI in Drug Discovery, Biomarker Development and Advanced R&D sector, thereby providing exposure to the entire industry. In this way, rather than betting on separate most-promising companies within the sector, the fund will appreciate capital based on the impending success of the entire AI in Pharma industry.


Market Intelligence


AI-Pharma fund will use market intelligence primarily delivered by the Pharma Division of Deep Knowledge Analytics, which has produced 20+ case studies and analytical reports focused on AI for Drug Discovery sector, setting the gold standard for analytics on this topic. DKA's Pharma Division will provide for the AI-Pharma fund sophisticated comparative industry analytics in order to develop and de-risk the fund's investment strategies. AI for Drug Discovery companies are highly complex and difficult for investors to evaluate. While roughly 170 companies are active in this sector, only a quarter of them can be expected to deliver clear and tangible results, whereas the probability and timelines of future success for the other three-quarters remain uncertain (applying AI for de novo molecule discovery, for example, being one of the most challenging deliverables for this sector). The Pharma Division of DKA applies quantified metrics and mathematical equations to perform deep comparative analysis of AI for Drug Discovery companies, comparing prospective investment targets using multiple parameters to differentiate levels of maturity and scientific and technical advantages to deploy relevant industry intelligence and analytics to develop and guide modern and applicable investment strategy for the AI for Drug Discovery sector.

AI-Pharma Investment Fund

- Competitive Minimum Entry Fees
- Enhanced Liquidity
- Offers Different Ratios of Liquidity to Profitability
- De-risking Investments by Betting on the Rise of Entire AI in Pharma Industry
- Capable of Beating Market Index via Active Portfolio Management
- Proven Track Record in Deep Analytics of the AI in Pharma Industry

Levels of AI Strength: 150 AI in Drug Discovery Companies





MANAGEMENT TEAM



DMITRY KAMINSKIY

GENERAL PARTNER

Dmitry Kaminskiy, based in London. He is an experienced AI in Pharma industry investor and entrepreneur, founder of Deep Knowledge Ventures and Aging Analytics Agency since 2014.



MARGARETTA COLANGELO

MANAGING PARTNER

Margaretta Colangelo, based in San Francisco, has 30+ years experience in executive, founder and advisory positions in the IT-industry.



STEFAN HASCOET

MANAGING PARTNER

Stefan Hascoet, based in Geneva, is the Capital Markets Professional with 15 years experience in investment products, derivatives and non-recourse lending facilities.



KATE BATZ

MANAGING PARTNER

Kate Batz, based in San Francisco, is licensed to practice law in California and New York. Lawyer with 20 years experience as a Corporate Attorney.



Provides Liquidity Similar to Hedge Funds Combined With Venture Fund Style Objectives



Invests in the top 10% of companies in the Longevity Industry. Based on the most advanced market intelligence.



The most sophisticated strategy to structure portfolio. Significantly de-risks the interests of LPs.



Bets on the success of the entire AI-Pharma sector, rather than the success of individual companies.